Filing Flows › Nurix Therapeutics (NRIX) › Q4 FY25
Nurix Therapeutics (NRIX) Q4 FY25 earnings results (fourth quarter fiscal 2025)
10-K filed Jan 28, 2026
Nurix Therapeutics (NRIX) reported revenue of $13.6M for the fourth quarter fiscal 2025 (Q4 FY25), +2% from a year earlier and +72% from the quarter before. Operating margin was -612.0%, net loss $78.2M (576.1% of revenue).
Nurix Therapeutics, Q4 FY25: revenue $13.6M (+2% year over year), operating margin -612.0%, net loss $78.2M, operating cash flow −$67.8M. The chart follows the revenue to costs, profit and cash.
| Q4 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $13.6M | +72% | +2% |
| Operating profit | −$83.1M | — | — |
| Net earnings | −$78.2M | — | — |
| Operating cash flow | −$67.8M | — | — |
What changed
Revenue was $13.6M in Q4 FY25, up 2% year over year and up 72% from the previous quarter.
Operating costs exceeded revenue by $83.1M, an operating margin of -612.0%. Total costs grew 24% against revenue growth of 2%. The fastest-growing cost line was General & admin (+27%). The quarter ended with a net loss of $78.2M, narrower than the previous quarter's $86.4M loss.
Operating cash flow was −$67.8M. Non-cash charges added back $2.1M of depreciation and amortization and $9.1M of share-based compensation. Capital expenditures of $5.1M exceeded it, leaving free cash flow of −$73.0M.
Questions
What was Nurix Therapeutics' revenue in the fourth quarter fiscal 2025?
Nurix Therapeutics (NRIX) reported revenue of $13.6M for the fourth quarter fiscal 2025 (Q4 FY25), +2% from a year earlier and +72% from the quarter before.
Was Nurix Therapeutics profitable in the fourth quarter fiscal 2025?
Operating loss was $83.1M (-612.0% of revenue) and net loss $78.2M.
Source: Nurix Therapeutics 10-K on SEC EDGAR.